<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921531</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-THALIDOMIDE</org_study_id>
    <secondary_id>LCI-09-06-15</secondary_id>
    <nct_id>NCT00921531</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase Ⅲ Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemoembolization (TACE) is used in the majority of advanced hepatocellular carcinomas.
      Randomized clinical trials indicated that TACE improves overall survival in patients with
      good liver function (Child-pugh A or B). However, the shortcoming of TACE is obvious: hypoxia
      induced neoangiogenesis after blockage of blood supply of the tumor; repeat TACE deteriorates
      liver cirrhosis due to toxicity of chemotherapeutic agent to the parenchyma liver.
      Thalidomide has been reported to have antiangiogenic and antimetastatic effects. The
      objectives of adjuvant therapy with thalidomide for chemoembolization is to evaluate overall
      survival and time to progression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>primary outcome is defined as overall survival. overall survival is calculated from the time of undergo treatment (TACE) to time of patients death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>36 months</time_frame>
    <description>time to progression is defined as from the time of treatment (TACE) to the time of patient's progression. the progression is defined as disease progression based on RECIST criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Thalidomide and TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide is used for adjuvant therapy for TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide is used for adjuvant therapy for TACE
Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day.</description>
    <arm_group_label>Thalidomide and TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.</description>
    <arm_group_label>Thalidomide and TACE</arm_group_label>
    <arm_group_label>TACE only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular carcinoma confirmed with pathology or identified with radiological
             images with typical features

          -  Age ≥ 18 years and ≤ 80 years

          -  At least one tumor nodule with one uni-dimension of ≥ 2 cm

          -  Child-Pugh Class A or B

          -  Total bilirubin ≤ 1.5 x upper limit of normal

          -  ALT and AST ≤ 2.0 x the upper limit of normal

          -  PT-INR&lt;2.3,PTT &lt; 1.5 x upper limit of normal

          -  Serum creatinine ≤ 1.5x upper limit of normal

          -  Peripheral white blood cell count of or more than 3×10(9)/L

          -  Peripheral platelet of or more than 50×10(9)/L

          -  Expected survival time not less than 3 months

          -  ECOG score 0-2

        Exclusion Criteria:

          -  Tumor thrombi in main branch of portal vein

          -  Tumor involvement more than 70% of whole liver

          -  With extrahepatic metastasis

          -  Prior systemic chemotherapy or chemoembolization

          -  Congestive heart failure &gt; NYHA class 2

          -  History of HIV infection

          -  Active clinically serious infections (&gt; 2 NCI-CTC Version 3.0)

          -  Recurrence of HCC after liver transplantation

          -  Pregnant or breast-feeding

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in this study

          -  Known or suspected allergy to any agent given in association with this trial

          -  Patients unable to swallow oral medication

          -  Inclined to thrombosis

          -  Inclined to hemorrhage or active hemorrhage with 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng-Gang Ren, Ph.D</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2137</phone_ext>
    <email>ren.zhenggang@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ju-Bo Zhang, Ph.D</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2136</phone_ext>
    <email>zhang.jubo@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Cancer Institute</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng-Gang Ren, Ph.D</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2137</phone_ext>
      <email>ren.zhenggang@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lan Zhang, Master</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2171</phone_ext>
      <email>zhang.lan@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zheng-Gang Ren, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jubo Zhang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fudan.edu.cn/</url>
    <description>Fudan University,Shanghai,China</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>ethic committee of Zhongshan Hospital of Fudan University</name_title>
    <organization>Fudan University</organization>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>thalidomide</keyword>
  <keyword>TACE</keyword>
  <keyword>Child-Pugh Class A or B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

